Trial · NCT02661100
A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients
NCT02661100, Phase 1, Phase 2, Withdrawn, Case Comprehensive Cancer Center
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients. Trials, record NCT02661100. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02661100
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients
- NCT number
- NCT02661100
- Status
- Withdrawn
- Phases
- Phase 1, Phase 2
- Enrollment
- 0 participants, actual
- Lead sponsor
- Case Comprehensive Cancer Center
- Conditions
- Non Small Cell Lung Cancer, Advanced Triple Negative Breast Cancer, Small Cell Lung Cancer, Urothelial Cancer, Mesothelioma, Malignant Melanoma
- Interventions
- Pembrolizumab, CDX-1401, Poly-ICLC
- First posted
- 2016-01-22
- Last updated
- 2016-12-07
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Dose Limiting Toxicity | Up to 28 days of therapy (Cycle 1) | Dose limiting toxicity (DLT) will be defined as any side effects which are attributable to the study treatment during the first 28 days of therapy (Cycle 1). The dose limiting toxicity will be based on the tolerability observed during treatment. |
| Secondary | Objective Response Rate for combination therapy | Up to 24 months after beginning treatment | Tumor response will be assessed using immune-related Response Criteria (irRC). The objective response rate will be estimated based on the crude proportion of patients who achieve complete response (CR) or partial response (PR). Complete response is defined as the disappearance of all lesions in two consecutive observations not less than 4 weeks apart. Partial response is defined as \>=50% decrease in tumor burden compared with baseline in two observations at least 4 weeks apart. |
| Secondary | Median Duration of Response | Up to 24 months after beginning treatment | Tumor response will be assessed using immune-related Response Criteria (irRC). The duration of response will be calculated from the time when the criteria for response are first met to the first documentation of relapse (after CR) or progression (after PR). Complete response is defined as the disappearance of all lesions in two consecutive observations not less than 4 weeks apart. Partial response is defined as \>=50% decrease in tumor burden compared with baseline in two observations at least 4 weeks apart. Stable disease is when 50% decrease in tumor burden compared with baseline cannot be established nor 25% increase compared with baseline. Progressive disease is defined as at least 25% increase in tumor burden compared with baseline in two consecutive observations at least 4 weeks apart. |
| Secondary | Median time to tumor response | Up to 24 months after beginning treatment | Tumor response will be assessed using immune-related Response Criteria (irRC). Complete response is defined as the disappearance of all lesions in two consecutive observations not less than 4 weeks apart. Partial response is defined as \>=50% decrease in tumor burden compared with baseline in two observations at least 4 weeks apart. Stable disease is when 50% decrease in tumor burden compared with baseline cannot be established nor 25% increase compared with baseline. Progressive disease is defined as at least 25% increase in tumor burden compared with baseline in two consecutive observations at least 4 weeks apart. |
| Secondary | Median time of progression free survival | Up to 24 months after beginning treatment | Time from beginning of treatment to disease progression. Progressive disease is defined as at least 25% increase in tumor burden compared with baseline in two consecutive observations at least 4 weeks apart. |
| Secondary | Median Overall Survival | Up to 24 months after beginning treatment | Defined as time from beginning of treatment until death, withdrawal of consent, or the end of the study, whichever occurs first. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02661100
GET https://conductscience.org/api/trials/v1/NCT02661100/registered